Vertex Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Vertex Pharmaceuticals
VRTX Stock  USD 512.23  1.53  0.30%   
Vertex Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Vertex Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vertex Pharmaceuticals financial statements helps investors assess Vertex Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vertex Pharmaceuticals' valuation are summarized below:
Gross Profit
9.5 B
Profit Margin
(0.05)
Market Capitalization
131.9 B
Enterprise Value Revenue
11.3659
Revenue
11 B
We have found one hundred twenty available fundamental trend indicators for Vertex Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vertex Pharmaceuticals current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 8.4 B in 2025. Enterprise Value is likely to drop to about 8.3 B in 2025

Vertex Pharmaceuticals Total Revenue

11.57 Billion

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.6 B, Gross Profit of 10 B or Other Operating Expenses of 11.8 B, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 7.39. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.7 B22.5 B9.1 B
Slightly volatile
Short and Long Term Debt Total1.8 B1.7 B763.7 M
Slightly volatile
Total Current Liabilities3.7 B3.6 B1.4 B
Slightly volatile
Total Stockholder Equity17.2 B16.4 B6.4 B
Slightly volatile
Property Plant And Equipment Net2.7 B2.6 B977.4 M
Slightly volatile
Cash4.8 B4.6 B3.4 B
Slightly volatile
Non Current Assets Total13.6 B12.9 B3.9 B
Slightly volatile
Non Currrent Assets Other1 B999.3 M421.1 M
Slightly volatile
Cash And Short Term Investments6.4 B6.1 B4.1 B
Slightly volatile
Common Stock Shares Outstanding156.8 M257.9 M225.7 M
Slightly volatile
Liabilities And Stockholders Equity23.7 B22.5 B9.1 B
Slightly volatile
Non Current Liabilities Total2.7 B2.6 B1.4 B
Slightly volatile
Other Current Assets699 M665.7 M304.1 M
Slightly volatile
Other Stockholder Equity3.5 B6.7 B5.9 B
Slightly volatile
Total Liabilities6.4 B6.1 B2.6 B
Slightly volatile
Total Current Assets10.1 B9.6 B5.2 B
Slightly volatile
Accounts Payable433.6 M413 M160.7 M
Slightly volatile
Property Plant And Equipment Gross3.8 B3.6 B1.4 B
Slightly volatile
Net Receivables1.7 B1.6 B657.6 M
Slightly volatile
Common Stock Total Equity1.9 M3 M2.3 M
Slightly volatile
Common Stock2 M3 M2.3 M
Slightly volatile
Other Assets1.7 B1.6 B668.5 M
Slightly volatile
Long Term Debt446.2 M646.2 M554.7 M
Pretty Stable
Short Term Investments1.6 B1.5 B685.2 M
Slightly volatile
Property Plant Equipment1.8 B1.7 B889.7 M
Slightly volatile
Other Liabilities828.1 M788.7 M385.2 M
Slightly volatile
Current Deferred Revenue118.8 M195.8 M139.2 M
Slightly volatile
Inventory1.3 B1.2 B314.8 M
Slightly volatile
Good Will1.3 B1.3 B581.8 M
Slightly volatile
Intangible Assets454.9 M825.9 M409.6 M
Slightly volatile
Long Term Debt Total632.6 M619.9 M574.7 M
Pretty Stable
Capital Surpluse6.9 B8.5 B6.5 B
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M92.7 M
Slightly volatile
Non Current Liabilities Other395.1 M203.2 M361.4 M
Slightly volatile
Capital Lease Obligations1.8 B1.7 B424.7 M
Slightly volatile
Short and Long Term Debt732.3 M697.4 M382.3 M
Slightly volatile
Long Term Investments5.4 B5.1 B850 M
Slightly volatile
Net Invested Capital10.9 B16.4 B6.5 B
Slightly volatile
Net Working Capital6.6 B6 B4.2 B
Slightly volatile
Capital Stock2.8 M3 M2.6 M
Slightly volatile

Vertex Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue11.6 B11 B4.5 B
Slightly volatile
Gross Profit10 B9.5 B3.9 B
Slightly volatile
Other Operating Expenses11.8 B11.3 B3.6 B
Slightly volatile
Total Operating Expenses10.2 B9.7 B3 B
Slightly volatile
Depreciation And Amortization217.6 M207.2 M105.9 M
Slightly volatile
Research Development3.8 B3.6 B1.7 B
Slightly volatile
Selling General Administrative1.5 B1.5 B666.9 M
Slightly volatile
Extraordinary Items1.9 B1.8 B1.5 B
Slightly volatile
Non Recurring102.7 M104 M122 M
Very volatile
Interest Income628 M598.1 M172.1 M
Slightly volatile
Reconciled Depreciation139.2 M207.2 M98.9 M
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.9 B10.4 B3.5 B
Slightly volatile
Depreciation217.6 M207.2 M96.3 M
Slightly volatile
Capital Expenditures312.6 M297.7 M148.1 M
Slightly volatile
End Period Cash Flow4.8 B4.6 B3.4 B
Slightly volatile
Stock Based Compensation733.4 M698.5 M335.5 M
Slightly volatile
Change To Netincome437.4 M512.4 M410.3 M
Slightly volatile
Issuance Of Capital Stock347.9 M394.7 M316.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.949.409614.6772
Slightly volatile
PTB Ratio7.396.319211.3995
Slightly volatile
Days Sales Outstanding58.2953.305449.8259
Slightly volatile
Book Value Per Share66.9163.726625.4264
Slightly volatile
Stock Based Compensation To Revenue0.06020.06340.1015
Slightly volatile
Capex To Depreciation1.11.43681.5365
Very volatile
PB Ratio7.396.319211.3995
Slightly volatile
EV To Sales8.79.153714.282
Slightly volatile
Inventory Turnover1.211.26973.297
Slightly volatile
Days Of Inventory On Hand302287171
Pretty Stable
Sales General And Administrative To Revenue0.260.210.2639
Slightly volatile
Research And Ddevelopement To Revenue0.310.32940.63
Slightly volatile
Capex To Revenue0.02570.0270.064
Slightly volatile
Cash Per Share24.9423.751116.1727
Slightly volatile
Intangibles To Total Assets0.140.08490.1227
Slightly volatile
Current Ratio2.562.692117.2981
Very volatile
Tangible Book Value Per Share59.1156.29421.9266
Slightly volatile
Receivables Turnover8.716.84737.9197
Slightly volatile
Shareholders Equity Per Share66.9163.726625.3026
Slightly volatile
Debt To Equity0.10.10660.3229
Slightly volatile
Capex Per Share1.211.15610.5961
Slightly volatile
Revenue Per Share44.9442.796517.8614
Slightly volatile
Interest Debt Per Share7.266.9133.1951
Slightly volatile
Debt To Assets0.07380.07760.1602
Slightly volatile
Graham Number13913257.3392
Slightly volatile
Operating Cycle358341217
Pretty Stable
Price Book Value Ratio7.396.319211.3995
Slightly volatile
Company Equity Multiplier2.441.37321.8266
Slightly volatile
Long Term Debt To Capitalization0.20.150.2017
Slightly volatile
Total Debt To Capitalization0.09150.09630.2132
Slightly volatile
Debt Equity Ratio0.10.10660.3229
Slightly volatile
Quick Ratio2.242.35416.5439
Very volatile
Cash Ratio1.221.281911.4623
Very volatile
Days Of Inventory Outstanding302287171
Pretty Stable
Days Of Sales Outstanding58.2953.305449.8259
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.511.60431.0581
Pretty Stable
Price To Book Ratio7.396.319211.3995
Slightly volatile
Fixed Asset Turnover2.554.26384.2911
Slightly volatile
Debt Ratio0.07380.07760.1602
Slightly volatile
Price Sales Ratio8.949.409614.6772
Slightly volatile
Asset Turnover0.250.48910.479
Very volatile
Gross Profit Margin1.090.86110.9345
Slightly volatile
Price Fair Value7.396.319211.3995
Slightly volatile

Vertex Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.4 B16.2 B17.3 B
Very volatile
Enterprise Value8.3 B15.8 B17.1 B
Very volatile

Vertex Fundamental Market Drivers

Forward Price Earnings29.5858
Cash And Short Term Investments6.1 B

Vertex Upcoming Events

5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue195.8 M118.8 M
Total Revenue11 B11.6 B
Cost Of Revenue1.5 B1.6 B
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.21  0.26 
Research And Ddevelopement To Revenue 0.33  0.31 
Capex To Revenue 0.03  0.03 
Revenue Per Share 42.80  44.94 
Ebit Per Revenue(0.02)(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY